Standigm Launches Artificial Intelligence-Driven Lead Optimization Service at BIO-Europe 2018 in Copenhagen, Denmark

Seoul, Korea, South, November 05, 2018 –(PR.com)– Standigm, a company using the cutting-edge Artificial Intelligence (AI) technology to drug discovery, unveiled its latest technology and launched the customized lead optimization service, “Standigm BEST®,” at the 24th annual BIO-Europe international partnering conference being held in November 5-7, 2018 in Copenhagen, Denmark.

“Standigm BEST®” is an AI-driven customer-friendly service that generates BEtter novel STructures. It provides lead optimization to improve customer’s desired properties such as potency, selectivity, and ADMET (Adsorption, Distribution, Metabolism, Excretion, and Toxicity). This service also can be utilized for fast-follow hit identification or patent fencing strategy.

“Standigm BEST® arouses the interest of pharmaceutical companies. One-to-one meetings have been scheduled with several leading pharmaceutical companies. We are expecting more deals than last year when Standigm Expander® was launched. Five contracts have been made from the meetings with global pharmas in BIO-Europe 2017,” said Jinhan Kim, the CEO and co-founder of Standigm.

Standigm Expander® is an AI-driven drug repurposing service that was launched in November, 2017.

“We have gained recognition for our AI technology by providing the Expander® service. In-house preclinical data for NASH and Parkinson’s disease also demonstrate our technology. We are increasing employment to meet the demands from pharmaceutical companies and develop more advanced AI technology.”

BIO-Europe is the Europe’s largest partnering conference for the biotechnology industry. It brings two thousand companies over 100 countries annually, offering high-profile workshop and panel participation, company pitches, and one-to-one meetings.

About Standigm

Standigm is a drug discovery company that searches therapeutic lead compounds by using advanced artificial intelligence trained on biomedical big data. We currently focus on predicting new indications for existing drugs, called drug repositioning, and their lead optimization through deeply trained AI model with molecular features of drugs. Standigm generated tens of drug candidates for cancers, Parkinson’s disease (PD), autism, fatty liver diseases (NASH) and more. Our candidates have been experimentally being validated with several collaboration partners, school of medicine Ajou university (PD, animal models), Korea institute of science and technology (autism, animal models) and a CRO for NASH (in-house, cell line, organ-on-a-chip, and animal models). Standigm was founded in May 2015 by three experts in artificial intelligence and systems biology from Samsung Advanced Institute of Technology. 12 members including 8 PhDs are joined currently. We raised about 3.4 million dollars of investments from LB Investment, Kakao Ventures, and Atinum Investment. For more information, please visit: www.standigm.com.